Indications
Vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see Section 5.1 for important information on the populations for which efficacy has been established).
Composition
- Active substance
- Diroximel fumarate (BIIB098)
- International name (INN)
- diroximel fumarate
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Vumerity
- Active substance
- Diroximel fumarate (BIIB098)
- ATC code
- L04AX07
- Therapeutic area
- Multiple Sclerosis, Relapsing-Remitting